Intravenous and Subcutaneous Administration of Desmopresssin (DDAVP) to Hemophiliacs: Pharmacokinetics and Factor VIII Responses

Summary

When desmopressin (DDAVP) is given to mild and moderate hemophiliacs intravenously (i. v.) or subcutaneously (s.c.), there is a very large between-patient variability for peak levels of factor VIII coagulant activity (VIII :C). To evaluate whether or not between-patient variability is related to DDAVP levels achieved in plasma, we measured drug levels in 14 hemophilic volunteers (VIII: C 2 to 31 U/dL) who were randomly given 0.3 μg/Kg of i. v. or s. c. DDAVP and crossed-over to the other treatment after an interval of 15–30 days. Peak DDAVP levels (C_max) were higher for i.v. DDAVP (p <0.02), times to peak levels (t_max) were shorter for i.v. DDAVP (p <0.001). There was no difference between the i.v. and s.c. routes for plasma DDAVP time curve (AUC) and half-life (ti/,), but there was much larger variability for pharmacokinetic parameters with i.v. than with s.c. DDAVP. Post-DDAVP VIII:C increased 3.4 ± 1.6 fold (i.v.) and 3.3 ±1.3 fold (s. c.) over baseline levels, with no significant correlation between peak VIII :C and DDAVP levels for either route of administration. These findings establish the s. c. route of DDAVP administration to be bioequivalent in effect to the i.v. route, albeit with less variability. At the DDAVP dosage used in this study and currently recommended for therapy, the VIII: C response is neither a function of the rate of absorption of the compound nor of the magnitude of its plasma concentration.

Keywords

Hemophilia - DDAVP - Vasopressin - Pharmacokinetics

• References

• 1 Mannucci PM. Desmopressin (DDAVP) for treatment of disorders of hemostasis. In: Progress in Hemostasis and Thrombosis. Coller BS. (ed.) Grune & Stratton; 1986. 8 19-45
• 2 De la Fuente B, Kasper CK, Rickies FR, Hover LW. xiesponse of patients with mild and moderate hemophilia A and von Willebrand’s disease to treatment with desmopressin. Ann Intern Med 1985; 103: 6-14
• 3 Mannucci PM, Canciani MT, Rota L, Donovan BS. Response of factor VIII/ von Willebrand factor to DDAVP in healthy subjects and patients with hemophilia A and von Willebrand’s disease. Br J Haematol 1981; 47: 283-293
• 4 Kohler M, Hellstern P, Reiter B, von Blohn G, Wenzel E. The subcutaneous administration of the vasopressin analogue l-deamino-8-D-arginine vaso-pressin in patients with von Willebrand’s disease and hemophilia. Klin Wochenschr 1984; 62: 543-548
• 5 De Silo L, Mariani G, Mazzucconi MG, Chistolini A, Tirindelli MC, Mandelli F. Comparison between subcutaneous and intravenous DDAVP in mild and moderate hemophilia A. Thromb Haemostas 1985; 54: 387-389
• 6 Köhler M, Hellstem P, Miyashita C, von Blohn G, Wenzel E. Comparative study of intranasal, subcutaneous and intravenous administration of deamino-D-arginine vasopressin (DDAVP). Thromb Haemostas 1986; 55: 108-111
• 7 Ruggeri ZM, Mannucci PM, Jeffcoate SL, Ingram G IC. Immunoradiometric assay of factor VIII related antigen. With observation in 32 patients with severe von Willebrand’s disease. Br J Haematol 1976; 33: 221-228
• 8 Sofroniew MW, Madlet M, Müller OH, Scriba PC. A method for the consistent production of high quality antisera to small peptide hormones. Fresenius Z Anal Chem 1978; 290: 163
• 9 Lundin S, Melin P, Vilhardt H. Plasma concentrations of 1-deamino-8-Darginine vasopressin after intragastric administration in the rat. Acta Endocrinol 1985; 198: 179-183
• 10 Greenwood FC, Hunter WM, Glover JS. The preparation of m[-labelled human growth honnone of high specific radioactivity. Biochem J 1963; 89: 114-123
• 11 Longo G, Mattucci M, Messori A, Morfini M, Rossi-Ferrini PL. Pharmacokinetics of a new heat-treated concentrate of factor VIII estimated by modelindependent methods. Thrombos Res 1986; 42: 471-476